Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …

Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …

Ovarian cancer is the second most common cause of gynecologic cancer death in women
around the world. The outcomes are complicated, because the disease is often diagnosed …

Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …

Preeclampsia (PE) is a leading cause for peripartal morbidity, especially if developing early
in gestation. To enable prophylaxis in the prevention of PE, pregnancies at risk of PE must …

Effective screening modalities are currently available for only a small subset of cancers, and
they generally have suboptimal performance with complicated procedures. Therefore, there …

INTRODUCTION The goal of earlier cancer detection is to identify the disease at a stage
when it can be effectively treated, thereby offering the patient a better chance of long-term …

Methylation patterns of circulating cell-free DNA (cfDNA) contain rich information about
recent cell death events in the body. Here, we present an approach for unbiased …